A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Vitamin K; Warfarin
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 21 Oct 2019 Planned primary completion date changed from 24 Sep 2019 to 17 May 2022.
- 21 Mar 2019 Planned End Date changed from 15 Oct 2021 to 17 May 2022.
- 21 Feb 2019 Planned End Date changed from 10 Sep 2021 to 15 Oct 2021.